The PNP Technology

E. coli PNP publications

Review articles

Behbahani TE, Rosenthal EL, Parker WB, Sorscher EJ (2019) Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck. Head & Neck 41: 1979-1983.

Parker WB and Sorscher EJ (2017) Use of E. coli purine nucleoside phosphorylase in the treatment of solid tumors. Current Pharmaceutical Design 23: 7027-7048.

Zhang Y, Parker WB, Sorscher EJ, Ealick SE (2005) PNP anticancer gene therapy. Current Topics in Medicinal Chemistry 5: 1259-1274.

Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, and Ealick SE (2003) Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem. Biol. 10: 1173-1181.

Primary publications

Parker WB, Allan PW, Waud WR, Hong J, Gilbert-Ross M, Achyut BR, Joshi D, Behbahani T, Rab R, Ealick SE, Sorscher EJ (2020) The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors. Cancer Chemother Pharmacol. 85: 573-583.

Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ (2015) Phase 1 dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Annals of Oncology 26: 1481-1487.

Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB (2012) In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemotherapy and Pharmacology 70: 321-329.

Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ (2011) Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase. Cancer Gene Therapy 18: 390-398. PMC3096718

Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, and Sorscher EJ (2004) Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the Escherichia coli Purine Nucleoside Phosphorylase Gene. Cancer Res. 64: 6610-6615.

Parker WB, Allan PW, Hassan AEA, Secrist JA III, Sorscher EJ, and Waud WR (2003) Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Therapy 10: 23-29.

Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, and Bennett LL Jr (1998) Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 55: 1673-1681.

Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, and Sorscher EJ (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Human Gene Therapy 8: 1637-1644.

Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, and Parker WB (1994) Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Therapy 1: 233-238.